Viridian Therapeutics, Inc. beat EPS estimates 50% of the time across 16 reported quarters (8 beats, 8 misses), averaging -0.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.97 | $-1.05 | -8.3% | Miss | |
| Q1 FY26 | $-1.06 | $-0.90 | +15.1% | Beat | |
| Q4 FY25 | $-0.90 | $-1.08 | -20.0% | Miss | |
| Q3 FY25 | $-0.82 | $-0.34 | +58.5% | Beat | |
| Q2 FY25 | $1.00 | $1.00 | +0.0% | Beat | |
| Q1 FY25 | $-0.95 | $-0.87 | +8.4% | Beat | |
| Q4 FY24 | $-1.05 | $-0.81 | +22.9% | Beat | |
| Q3 FY24 | $-1.11 | $-1.15 | -3.6% | Miss | |
| Q2 FY24 | $-0.87 | $-1.02 | -17.2% | Miss | |
| Q1 FY24 | $-1.07 | $-0.79 | +26.2% | Beat | |
| Q4 FY23 | $-1.08 | $-1.35 | -25.0% | Miss | |
| Q3 FY23 | $-1.22 | $-1.09 | +10.7% | Beat |
Back to VRDN overview · VRDN holders · VRDN KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.